Skip to main content
OpenTrials

Clinical trial condition

Paraproteinemias

Explore clinical trials studying Paraproteinemias. Study availability and eligibility vary by location and protocol.

3,043 public trials 577 recruiting studies
Refine in advanced search Browse all conditions

Paraproteinemias trial results

Recruiting

A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma

NCT06980480

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Infirmary Health - Diagnostic & Medical Clinic (DMC) Mobile, Alabama, United States
  • Chao Family Comprehensive Cancer Center UCI Orange, California, United States
  • University of Kansas Westwood, Kansas, United States
  • University of Maryland | Greenebaum Cancer Center Baltimore, Maryland, United States
View all 56 locations
View Trial Details
Recruiting

A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma

NCT07637578

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +19 more
Locations
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Willamette Valley Cancer Institute and Research Center Eugene, Oregon, United States
  • SCRI Oncology Partners Nashville, Tennessee, United States
  • Rocky Mountain Cancer Center Denver, Colorado, United States
View Trial Details
Recruiting

RAT-HEMATO : Return to Work After Malignant Hemopathy

NCT06262789

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +15 more
Locations
  • Angers University hospital Angers, France
  • Brest University Hospital, Morvan Site Brest, France
  • Caen University hospital Caen, France
  • Rennes University Hospital, Pontchaillou site Rennes, France
View Trial Details
Recruiting

A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma

NCT05583617

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Prince of Wales Hospital Randwick, New South Wales, Australia
  • St Vincent's Hospital Melbourne Fitzroy, Victoria, Australia
  • CHU Lyon Sud - Service Hématologie Pierre-Bénite, France
  • IUCT Oncopole Toulouse, France
View all 16 locations
View Trial Details
Recruiting

A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

NCT05927571

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • Royal Prince Alfred Hospital Camperdown, New South Wales, Australia
  • Calvary Mater Newcastle Waratah, New South Wales, Australia
  • Royal Adelaide Hospital;Haematology Clinical Trials Unit Adelaide, South Australia, Australia
  • St. Vincent's Hospital Melbourne Melbourne, Victoria, Australia
View all 14 locations
View Trial Details
Recruiting

A Study to Assess the Effectiveness and Safety of Canakinumab in Clinical Use in Patients With Schnitzler's Syndrome

NCT07598422

Conditions
Immune System Diseases, Immunoproliferative Disorders, Monoclonal Gammopathy of Undetermined Significance, +2 more
Locations
  • Novartis Investigative Site Osaka, Japan
  • Novartis Investigative Site Kobe, Hyōgo, Japan
  • Novartis Investigative Site Ushiku, Ibaraki, Japan
  • Novartis Investigative Site Kanoya, Kagoshima-ken, Japan
View Trial Details

Related conditions